美国安进地舒单抗进医保了吗？

Helps reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. This product is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures. So, has Amgen denosumab been included in medical insurance in the United States?

Desosumab has not yet been included in the medical insurance in China. Overseas, a box of denosumab produced by Amgen in the United States is only about $1,500. Compared with the same period last year, the price of the original research drug sold in China has dropped. Patients in need can purchase medicines abroad or obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel), which can be delivered directly to their homes to ensure authenticity.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

Data from a study of Amgen's denosumab: Compared with zoledronic acid, denosumab was better at preventing complications of bone metastases from solid tumors or multiple myeloma. Compared with zoledronic acid, denosumab can significantly delay the onset of SREs in patients with breast cancer bone metastases, reduce the risk of multiple SREs by 23%, significantly delay the onset of pain by 3.9 months, and reduce the use of powerful opioid analgesics. In addition, subcutaneous injection of denosumab has greatly improved patients' medication compliance.

RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Amgen's is the first approved monoclonal antibody specifically targeting a RANK ligand. It can block the formation of multinucleated giant cells, thereby inhibiting the pathological process of osteolysis and destruction of giant cell tumors of bone and restoring bone formation. It has been clinically proven to have a good anti-tumor effect on giant cell tumors of bone.